Roche Teams Up With Ascidian Therapeutics for RNA Gene Editing Deal
By Helena Smolak
Roche will partner with U.S. biotech company Ascidian Therapeutics to develop gene therapies through its RNA exon editing technology--a method that edits exons at the kilobase level, instead of direct DNA modification--to treat neurological diseases.
The Boston-based startup said Tuesday that it would receive $42 million from Roche as an initial payment, in addition to up to $1.8 billion in research, clinical and commercial milestone payments.
Ascidian will conduct discovery and pre-clinical activities with Roche and will provide the Swiss drugmaker its rights to RNA exon editing technology for undisclosed neurological targets, it said.
The deal is complementary to Roche's own gene editing strategy and aims to benefit its neuroscience portfolio over the next five years, Roche said.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
June 18, 2024 08:54 ET (12:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What’s Happening In the Markets This Week
-
What a Strong Economy Now Means for the Rest of 2024
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
Investment Opportunities in US Renewable Energy
-
10 Best Value Stocks to Buy for the Long Term
-
A Wide-Moat Stock to Invest in That’s 35% Undervalued
-
Airbus: We Believe Investors May Be Overreacting to Lowered Guidance and Charge
-
10 Stocks the Best Fund Managers Have Been Selling
-
TSMC Fair Value Raised 45% on Stronger AI Demand
-
3 International Stocks the Best Managers Have Been Buying
-
After Earnings, Is Adobe Stock a Buy, a Sell, or Fairly Valued?